CVie Therapeutics Co. Ltd. Report issue

For profit Phase 1 Phase 2 Phase 4
Founded: Hong Kong Hong Kong (2012)
Status: Acquired by Windtree Therapeutics (2018)

Organization Overview

First Clinical Trial
2015
NCT02477449
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

CVie Therapeutics Limited | Cvie Therapeutics Ltd.

Active Ingredients

Drugs in Phase 4 Trials (1)

treprostinil (remodulin) (2 trials)

Drugs in Phase 2 Trials (3)

istaroxime (2 trials)

losartan (cozaar) (1 trial)

rostafuroxin (1 trial)

Drugs in Phase 1 Trials (1)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Familial Primary Pulmonary Hypertension (Phase 4)

Heart Failure (Phase 2)

Hypertension (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 5